Moving to Nox inhibition, the dual Nox1/4 inhibitor setanaxib (GKT137831) has been investigated in the experimental setting of doxorubicin-, angiotensin II-, and hypertension-induced cardiac remodeling, displaying cardioprotective effects based on antioxidant and antifibrotic action [158,159,160]. Here, NOX1 is linked to hypertensive disorder.